Related Experiment Video
Updated: Sep 10, 2025

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
When is it time to bid farewell to anticoagulation?
Julia Czuprynska1, Roopen Arya1
1Department of Haematological Medicine, King's Thrombosis Centre, King's College Hospital NHS Foundation Trust, London, UK.
Abstract:
Decisions about antithrombotic therapy in cancer patients at the end of life can be challenging. This cohort study examined prescribing behaviour and outcomes relating to antithrombotic therapy in this patient group, finding that deprescribing was uncommon. Greater awareness of this neglected but high-risk aspect of patient care is required along with interventions to enable shared decision-making in this setting. Commentary on: Aldridge et al. Antithrombotic therapy in patients with cancer at the end of life and associated clinical outcomes: a cohort study using population-linked routinely collected data. Br J Haematol 2025;207:2080-2090.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis IV: Nursing Management
Pulmonary Embolism III: Nursing Management
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

